Primary vaccine failure after 1 dose of varicella vaccine in healthy children

Journal of Infectious Diseases

Volumn 197, Issue 7, 2008, Pages 944-949

  Michalik, David E ^a   Steinberg, Sharon P ^a   LaRussa, Philip S ^a   Edwards, Kathryn M ^b   Wright, Peter F ^b   Arvin, Ann M ^c   Gans, Haley A ^c   Gershon, Anne A ^a,d  

^a NewYork Presbyterian Hospital   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d Black Bldg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; BLOOD SAMPLING; CHICKENPOX; CHILD; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; NORMAL HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SEROCONVERSION; UNITED STATES; VACCINE FAILURE; VARICELLA ZOSTER VIRUS;

ANTIBODIES, VIRAL; CALIFORNIA; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; FLUORESCENT ANTIBODY TECHNIQUE; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; NEW YORK; TENNESSEE;

EID: 42549132378     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/529043     Document Type: Article

References (43)

1. Arvin AM, Sharp M, Moir M, et al. Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus. Viral Immunol 2002; 15:507-16.
2. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 2:1288-90.
3. Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the Oka strain of live varicella vaccine. Pediatrics 1985; 75:667-71.
4. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23:132-7.
5. LaRussa P, Steinberg S, Waithe E, Hanna B, Holzman R. Comparison of five assays for antibody to varicella-zoster virus and the fluorescent-antibody-to- membrane-antigen test. J Clin Microbiol 1987; 25:2059-62.
6. Saiman L, LaRussa P, Steinberg S, et al. Persistence of immunity to varicella-zoster virus vaccination among health care workers. Infect Control Hosp Epidemiol 2001; 22:279-83.
7. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991; 9:111-6.
8. Krah DL, Cho I, Schofield T, Ellis RW. Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (VarivaxR) in children and adults. Vaccine 1997; 15:61-4.
9. Li S, Chan I, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002; 21:337-42.
10. Lieberman JM, Williams WR, Miller JM, et al. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J 2006; 25:615-22.
11. Williams V, Gershon A, Brunell P. Serologic response to varicella-zoster membrane antigens measured by indirect immunofluorescence. J Infect Dis 1974; 130:669-72.
12. Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 2002; 34:774-9.
13. Gershon AA, Steinberg S, Gelb L, NIAID Collaborative Varicella Vaccine Study Group. Live attenuated varicella vaccine: efficacy for children with leukemia in remission. JAMA 1984; 252:355-62.
14. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997; 278:1495-9.
15. Galil K, Fair E, Mountcastle N, Britz P, Seward J. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis 2002; 186:102-5.
16. Dworkin MS, Jennings CE, Roth-Thomas J, Lang JE, Stukenberg C, Lumpkin JR. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis 2002; 35:102-4.
17. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 2002; 347:1909-15.
18. Tugwell BD, Lee LE, Gillette H, Lorber EM, Hedberg K, Cieslak PR. Chickenpox outbreak in a highly vaccinated school population. Pediatrics 2004; 113:455-9.
19. Centers for Disease Control. Outbreak of varicella among vaccinated children - Michigan, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:389-92.
20. Lee BR, Feaver SL, Miller CA, Hedberg CW, Ehresmann KR. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis 2004; 190:477-83.
21. Marin M, Nguyen HQ, Keen J, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics 2005; 115:900-5.
22. Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics 2005; 115:1488-93.
23. Arnedo-Pena A, Puig-Barbera J, Aznar-Orenga MA, et al. Varicella vaccine effectiveness during an outbreak in a partially vaccinated population in Spain. Pediatr Infect Dis J 2006; 25:774-8.
24. Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics 2006; 117:e1070-7.
25. Gershon A, Takahashi M, Seward J. Varicella vaccine. In: Plotkin S, Orenstein W, eds. Vaccines. 5th ed. Philadelphia: Saunders (in press).
26. Vazquez M, LaRussa P, Gershon A, Steinberg S, Freudigman K, Shapiro E. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001; 344:955-60.
27. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291:851-5.
28. Gershon A, Kalter Z, Steinberg S. Detection of antibody to varicella-zoster virus by immune adherence hemagglutination. Proc Soc Exp Biol Med 1976; 151:762-5.
29. Gershon A, Steinberg S, LaRussa P. Detection of antibodies to varicella-zoster virus by latex agglutination. Clin Diagn Virol 1994; 2:271-7.
30. Gershon A. Varicella-zoster virus: prospects for control. Adv Pediatr Infect Dis 1995; 10:93-124.
31. Presissner C, Steinberg S, Gershon A, Smith TF. Evaluation of the anticomplement immunofluorescence test for detection of antibody to varicella-zoster virus. J Clin Microbiol 1982; 16:373-6.
32. Steinberg S, Gershon A. Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. J Clin Microbiol 1991; 29:1527-9.
33. Ross AH, Lencher E, Reitman G. Modification of chickenpox in family contacts by administration of gamma globulin. N Engl J Med 1962; 267:369-76.
34. Gershon AA, Steinberg S, Gelb L, NIAID Collaborative Varicella Vaccine Study Group. Clinical reinfection with varicella-zoster virus. J Infect Dis 1984; 149:137-42.
35. Junker AK, Angus E, Thomas E. Recurrent varicella-zoster virus infections in apparently immunocompetent children. Pediatr Infect Dis J 1991; 10:569-75.
36. Gershon A, Krugman S. Seroepidemiological survey of varicella: value of specific immunofluorescent antibody test. Pediatrics 1975; 56:1005.
37. LaRussa P, Steinberg S, Seeman MD, Gershon AA. Determination of immunity to varicella by means of an intradermal skin test. J Infect Dis 1985; 152:869-75.
38. Gershon AA, Steinberg S, NIAID Collaborative Varicella Vaccine Study Group. Live attenuated varicella vaccine: protection in healthy adults in comparison to leukemic children. J Infect Dis 1990; 161:661-6.
39. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA 2004; 292:704-8.
40. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007; 356:1121-9.
41. Gershon A, Raker R, Steinberg S, Topf-Oldstein B, Drusin L. Antibody to varicella-zoster virus in parturient women and their offspring during the first year of life. Pediatrics 1976; 58:692-6.
42. Shinefield H, Black S, Staehle B, et al. Vaccination with measles, mumps, and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody, and duration of protection against varicella in healthy children. Pediatr Infect Dis J 2002; 21:555-61.
43. Johnson CE, Shurin PA, Fattlar D, et al. Live attenuated varicella vaccine in healthy 12- to 24-month old children. Pediatrics 1988; 81:512-8.